NASDAQ:LGVN Longeveron (LGVN) Stock Price, News & Analysis $3.44 +0.40 (+13.16%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.08▼$3.4550-Day Range$0.82▼$4.5552-Week Range$0.77▼$35.60Volume2.98 million shsAverage Volume5.37 million shsMarket Capitalization$21.84 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Longeveron alerts: Email Address Longeveron MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside248.8% Upside$12.00 Price TargetShort InterestBearish50.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.87) to ($2.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.76 out of 5 starsMedical Sector689th out of 936 stocksPharmaceutical Preparations Industry320th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingLongeveron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLongeveron has only been the subject of 1 research reports in the past 90 days.Read more about Longeveron's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted50.00% of the float of Longeveron has been sold short.Short Interest Ratio / Days to CoverLongeveron has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longeveron has recently increased by 651.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLongeveron does not currently pay a dividend.Dividend GrowthLongeveron does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LGVN. Previous Next 2.4 News and Social Media Coverage News SentimentLongeveron has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Longeveron this week, compared to 1 article on an average week.Search InterestOnly 15 people have searched for LGVN on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat Follows9 people have added Longeveron to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Longeveron insiders have not sold or bought any company stock.Percentage Held by Insiders19.12% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.01% of the stock of Longeveron is held by institutions.Read more about Longeveron's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Longeveron are expected to grow in the coming year, from ($3.87) to ($2.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longeveron is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longeveron is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongeveron has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Longeveron's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Longeveron Stock (NASDAQ:LGVN)Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.Read More LGVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGVN Stock News HeadlinesJuly 19, 2024 | globenewswire.comLongeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 18, 2024 | globenewswire.comLongeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 18, 2024 | globenewswire.comLongeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 17, 2024 | investorplace.comLGVN Stock Alert: Longeveron Pops 18% on FDA Fast-Track DesignationJuly 10, 2024 | investorplace.comWhy Is Longeveron (LGVN) Stock Up 53% Today?July 10, 2024 | globenewswire.comLongeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's DiseaseJuly 9, 2024 | globenewswire.comNeha Motwani Elected to Longeveron® Board of DirectorsJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 8, 2024 | globenewswire.comGene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of DirectorsJune 19, 2024 | investorplace.com3 Penny Stocks Poised to Turn Pocket Change Into a Small Fortune by 2028June 18, 2024 | globenewswire.comLongeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise TransactionJune 17, 2024 | globenewswire.comLongeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024June 17, 2024 | globenewswire.comLongeveron Announces Exercise of Warrants for $4.4 Million Gross ProceedsJune 13, 2024 | investorplace.comWhy Is Longeveron (LGVN) Stock Up 46% Today?June 12, 2024 | investorplace.comWhy Is Longeveron (LGVN) Stock Up 120% Today?June 3, 2024 | globenewswire.comLongeveron® Announces Contract Development and Manufacturing Business and First ContractMay 29, 2024 | benzinga.comAcumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News SummarySee More Headlines Receive LGVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LGVN CUSIPN/A CIK1721484 Webwww.longeveron.com Phone305-302-7158FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+271.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($9.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,410,000.00 Net Margins-2,129.24% Pretax Margin-2,129.24% Return on Equity-300.96% Return on Assets-164.96% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual Sales$710,000.00 Price / Sales28.89 Cash FlowN/A Price / Cash FlowN/A Book Value$2.68 per share Price / Book1.21Miscellaneous Outstanding Shares6,350,000Free Float5,135,000Market Cap$20.51 million OptionableNot Optionable Beta0.43 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Joshua Michael Hare FACC (Age 61)M.D., Co-Founder, Chief Science Officer & Chairman Comp: $74kMr. Mohamed Wa'el Ahmed Hashad (Age 62)CEO & Director Comp: $781.56kMs. Lisa A. Locklear M.B.A. (Age 62)Executive VP & CFO Comp: $248.38kMr. Paul T. Lehr J.D. (Age 56)International Executive Director, General Counsel & Secretary Comp: $554.05kDr. Dan Gincel Ph.D. (Age 53)Senior Vice President of Strategic Collaborations & Scientific Affairs Dr. Nataliya Agafanova M.D. (Age 54)Chief Medical Officer Ms. Elly Ryu (Age 42)VP & Corporate Controller More ExecutivesKey CompetitorsVincerx PharmaNASDAQ:VINCBrainstorm Cell TherapeuticsNASDAQ:BCLILisata TherapeuticsNASDAQ:LSTAPluriNASDAQ:PLUREyenoviaNASDAQ:EYENView All CompetitorsInsidersRock SofferBought 31,915 shares on 4/11/2024Total: $75,000.25 ($2.35/share)Mohamed Wa'el Ahmed HashadBought 10,638 shares on 4/11/2024Total: $24,999.30 ($2.35/share)Joshua HareBought 106,383 shares on 4/10/2024Total: $250,000.05 ($2.35/share)Cathy RossBought 500 shares on 1/10/2024Total: $6,550.00 ($13.10/share)Jeffrey PfefferBought 1,000 shares on 12/28/2023Total: $13,500.00 ($13.50/share)View All Insider Transactions LGVN Stock Analysis - Frequently Asked Questions How have LGVN shares performed this year? Longeveron's stock was trading at $13.60 at the beginning of the year. Since then, LGVN stock has decreased by 74.7% and is now trading at $3.44. View the best growth stocks for 2024 here. How were Longeveron's earnings last quarter? Longeveron Inc. (NASDAQ:LGVN) released its quarterly earnings results on Tuesday, May, 14th. The company reported ($1.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.01) by $0.40. The company earned $0.55 million during the quarter, compared to analysts' expectations of $0.12 million. Longeveron had a negative net margin of 2,129.24% and a negative trailing twelve-month return on equity of 300.96%. When did Longeveron's stock split? Longeveron shares reverse split before market open on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Longeveron IPO? Longeveron (LGVN) raised $30 million in an initial public offering on Friday, February 12th 2021. The company issued 2,700,000 shares at $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. served as the underwriters for the IPO. How do I buy shares of Longeveron? Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LGVN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
